曲妥珠单抗重组冻干粉针治疗转移性HER2阳性涎腺导管癌患者的疗效：病例系列报告 - Suppr

Response to fam-Trastuzumab-Deruxtecan in patients with metastatic HER2-positive salivary duct carcinoma: A case series.

作者信息

Boey Jaryl Jia Hao, Ng Kennedy Yao Yi, Krisnadi Cindy, Lim Darren Wan-Teck, Ang Mei-Kim

机构信息

Division of Medical Oncology, National Cancer Centre Singapore, Singapore.

Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore.

出版信息

Oral Oncol. 2023 Nov;146:106566. doi: 10.1016/j.oraloncology.2023.106566. Epub 2023 Sep 21.

DOI:10.1016/j.oraloncology.2023.106566

PMID:37741018

Abstract

摘要

相似文献

Response to fam-Trastuzumab-Deruxtecan in patients with metastatic HER2-positive salivary duct carcinoma: A case series.曲妥珠单抗重组冻干粉针治疗转移性HER2阳性涎腺导管癌患者的疗效：病例系列报告

Oral Oncol. 2023 Nov;146:106566. doi: 10.1016/j.oraloncology.2023.106566. Epub 2023 Sep 21.

Excellent Response to Fam-Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma With CNS Metastasis: A Case Report.曲妥珠单抗德鲁昔单抗治疗伴中枢神经系统转移的人表皮生长因子受体2阳性涎腺导管癌疗效显著：一例报告

JCO Precis Oncol. 2022 Nov;6:e2200399. doi: 10.1200/PO.22.00399.

Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan.伴有 ERBB2 扩增的转移性腮腺腺癌对氟马替尼-曲妥珠单抗偶联物完全缓解。

J Natl Compr Canc Netw. 2022 Feb;20(2):102-104. doi: 10.6004/jnccn.2021.7089.

Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.多西他赛、曲妥珠单抗和帕妥珠单抗（DTP）作为一线抗 HER2 治疗，阿替利珠单抗联合曲妥珠单抗和美坦新（T-DM1）作为二线治疗复发性或转移性 HER2 阳性唾液腺癌的病例系列。

Oral Oncol. 2022 Feb;125:105703. doi: 10.1016/j.oraloncology.2021.105703. Epub 2022 Jan 4.

A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.曲妥珠单抗-德鲁替康偶联物（fam-trastuzumab deruxtecan-nxki）治疗 HER2 阳性乳腺癌的研究进展

Ann Pharmacother. 2021 Nov;55(11):1410-1418. doi: 10.1177/1060028021998320. Epub 2021 Feb 25.

Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.病例报告：曲妥珠单抗作为人表皮生长因子受体 2 阳性唾液腺癌二线治疗。

Anticancer Drugs. 2022 Jan 1;33(1):e760-e763. doi: 10.1097/CAD.0000000000001181.

Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.人表皮生长因子受体 2 高表达唾液腺癌对曲妥珠单抗、帕妥珠单抗和多西他赛的显著反应。

Head Neck. 2018 Dec;40(12):E100-E106. doi: 10.1002/hed.25392. Epub 2018 Nov 26.

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.曲妥珠单抗-德鲁替康（DS-8201a）诱导的抗肿瘤免疫受抗 CTLA-4 抗体促进作用于小鼠模型。

PLoS One. 2019 Oct 1;14(10):e0222280. doi: 10.1371/journal.pone.0222280. eCollection 2019.

A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.多西他赛-PM 和曲妥珠单抗-pkrb 联合治疗复发性或转移性涎腺癌的 2 期多中心研究。

Cancer. 2023 Oct 1;129(19):2966-2974. doi: 10.1002/cncr.34892. Epub 2023 May 28.

Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.人表皮受体 2 扩增的唾液腺导管癌：双重人表皮受体 2 抑制和抗血管内皮生长因子联合治疗的消退。

Head Neck. 2014 Mar;36(3):E25-7. doi: 10.1002/hed.23429. Epub 2013 Oct 19.

引用本文的文献

Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report.曲妥珠单抗-德卢替康在一名接受过多种治疗的ERBB2扩增型腮腺癌患者中显示出令人感兴趣的疾病控制效果，一例病例报告。

Ther Adv Med Oncol. 2025 Jun 3;17:17588359251334071. doi: 10.1177/17588359251334071. eCollection 2025.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Response to fam-Trastuzumab-Deruxtecan in patients with metastatic HER2-positive salivary duct carcinoma: A case series.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献